GBT Announces New Employment Inducement Grants
May 07 2020 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced
that on May 1, 2020, the compensation committee of GBT’s board of
directors granted seven new employees restricted stock units for an
aggregate of 36,500 shares of the company’s common stock. These
awards were made under GBT’s Amended and Restated 2017 Inducement
Equity Plan (the Plan).
The above-described awards were each granted as
an inducement material to the employees entering into employment
with the company in accordance with NASDAQ Listing Rule 5635(c)(4),
and were granted pursuant to the terms of the Plan. The 2017
Inducement Equity Plan was adopted by GBT’s board of directors in
January 2017 and has been amended and restated from time to
time.
About Global Blood
TherapeuticsGlobal Blood Therapeutics (GBT) is a
biopharmaceutical company dedicated to the discovery, development
and delivery of life-changing treatments that provide hope to
underserved patient communities. Founded in 2011, GBT is delivering
on its goal to transform the treatment and care of sickle cell
disease (SCD), a lifelong, devastating inherited blood disorder.
The company has introduced Oxbryta® (voxelotor), the first
FDA-approved treatment that directly inhibits sickle hemoglobin
polymerization, an underlying cause of SCD. GBT is also advancing
its pipeline program in SCD with inclacumab, a p-selectin inhibitor
in development to address pain crises associated with the disease.
In addition, GBT’s drug discovery teams are working on new targets
to develop the next generation of treatments for SCD. To learn
more, please visit www.gbt.com and follow the company on Twitter
@GBT_news.
Contact Information:Steven
Immergut (media)650-410-3258simmergut@gbt.com
Stephanie Yao
(investors)650-741-7730syao@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024